401 related articles for article (PubMed ID: 27021303)
1. Allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A single center experience.
Schmohl JU; Groh C; Faul C; Vogel W; Möhle R; Wirths S; Schneidawind D; Kanz L; Bethge WA
Ann Hematol; 2016 May; 95(6):973-83. PubMed ID: 27021303
[TBL] [Abstract][Full Text] [Related]
2. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
3. Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
McLornan D; Szydlo R; Koster L; Chalandon Y; Robin M; Wolschke C; Beelen D; Socié G; Bornhäuser M; Angelucci E; Niederwieser D; Gerbitz A; Finke J; Vitek A; Itälä-Remes M; Radujkovic A; Kanz L; Potter V; Chevallier P; Stelljes M; Petersen E; Robinson S; Poiré X; Klyuchnikov E; Hernández-Boluda JC; Czerw T; Hayden P; Kröger N; Yakoub-Agha I
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2167-2171. PubMed ID: 31284069
[TBL] [Abstract][Full Text] [Related]
4. Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis.
Lissandre S; Bay JO; Cahn JY; Porcher R; Cacheux V; Cabrespine A; Cornillon J; Cassinat B; Peffault de Latour R; Socie G; Robin M
Bone Marrow Transplant; 2011 Apr; 46(4):557-61. PubMed ID: 21042309
[TBL] [Abstract][Full Text] [Related]
5. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
[TBL] [Abstract][Full Text] [Related]
6. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
[TBL] [Abstract][Full Text] [Related]
7. Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.
Robin M; Porcher R; Wolschke C; Sicre de Fontbrune F; Alchalby H; Christopeit M; Cassinat B; Zabelina T; Peffault de Latour R; Ayuk F; Socié G; Kröger N
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1206-1211. PubMed ID: 26970380
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of allogeneic haemopoietic stem cell transplants at a small New Zealand centre: does size matter?
Ganly P; Cole S; Trengrove A; Butler A
Intern Med J; 2014 Jul; 44(7):683-9. PubMed ID: 24750295
[TBL] [Abstract][Full Text] [Related]
9. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
10. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.
Abdul Wahid SF; Ismail NA; Mohd-Idris MR; Jamaluddin FW; Tumian N; Sze-Wei EY; Muhammad N; Nai ML
Stem Cells Dev; 2014 Nov; 23(21):2535-52. PubMed ID: 25072307
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic cell transplantation for chronic myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk.
Nivison-Smith I; Dodds AJ; Butler J; Bradstock KF; Ma DD; Simpson JM; Szer J
Biol Blood Marrow Transplant; 2012 Feb; 18(2):302-8. PubMed ID: 21620988
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation.
Shimoni A; Labopin M; Savani B; Volin L; Ehninger G; Kuball J; Bunjes D; Schaap N; Vigouroux S; Bacigalupo A; Veelken H; Sierra J; Eder M; Niederwieser D; Mohty M; Nagler A
J Hematol Oncol; 2016 Nov; 9(1):118. PubMed ID: 27821187
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
14. Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis.
Sibai H; Falcone U; Deotare U; Michelis FV; Uhm J; Gupta V; Kuruvilla J; Lipton JH; Seftel MD; Messner HA; Kim DDH
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2270-2275. PubMed ID: 27596129
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study.
Çiftçiler R; Göker H; Demiroğlu H; Aladağ E; Aksu S; Haznedaroğlu İC; Sayınalp N; Özcebe O; Tekin F; Büyükaşık Y
Turk J Haematol; 2019 May; 36(2):88-96. PubMed ID: 30717586
[TBL] [Abstract][Full Text] [Related]
16. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.
Epperla N; Ahn KW; Ahmed S; Jagasia M; DiGilio A; Devine SM; Jaglowski S; Kennedy V; Rezvani AR; Smith SM; Sureda A; Fenske TS; Kharfan-Dabaja MA; Armand P; Hamadani M
J Hematol Oncol; 2017 Jun; 10(1):117. PubMed ID: 28606176
[TBL] [Abstract][Full Text] [Related]
17. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.
Murthy GSG; Kim S; Estrada-Merly N; Abid MB; Aljurf M; Assal A; Badar T; Badawy SM; Ballen K; Beitinjaneh A; Cerny J; Chhabra S; DeFilipp Z; Dholaria B; Perez MAD; Farhan S; Freytes CO; Gale RP; Ganguly S; Gupta V; Grunwald MR; Hamad N; Hildebrandt GC; Inamoto Y; Jain T; Jamy O; Juckett M; Kalaycio M; Krem MM; Lazarus HM; Litzow M; Munker R; Murthy HS; Nathan S; Nishihori T; Ortí G; Patel SS; Van der Poel M; Rizzieri DA; Savani BN; Seo S; Solh M; Verdonck LF; Wirk B; Yared JA; Nakamura R; Oran B; Scott B; Saber W
Haematologica; 2023 Jul; 108(7):1900-1908. PubMed ID: 36779595
[TBL] [Abstract][Full Text] [Related]
18. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.
Snyder DS; Palmer J; Gaal K; Stein AS; Pullarkat V; Sahebi F; Vora N; Nakamura R; Forman SJ
Biol Blood Marrow Transplant; 2010 Feb; 16(2):281-6. PubMed ID: 19786111
[TBL] [Abstract][Full Text] [Related]
19. Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission.
Eom KS; Shin SH; Yoon JH; Yahng SA; Lee SE; Cho BS; Kim YJ; Kim HJ; Min CK; Kim DW; Lee JW; Min WS; Park CW; Lee S
Am J Hematol; 2013 Aug; 88(8):634-41. PubMed ID: 23620000
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years.
Daghia G; Zabelina T; Zeck G; von Pein UM; Christopeit M; Wolschke C; Ayuk F; Kröger N
Eur J Haematol; 2019 Oct; 103(4):370-378. PubMed ID: 31306511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
